Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1617sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 43	Feb 13	CANCERLIT is no longer being updated
NEWS 44	Feb 24	METADEX enhancements
NEWS 45	Feb 24	PCTGEN now available on STN
NEWS 46	Feb 24	TEMA now available on STN

```
 NEWS 47  Feb 26  NTIS now allows simultaneous left and right truncation
 NEWS 48  Feb 26  PCTFULL now contains images
 NEWS 49  Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 14:10:12 ON 14 MAR 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.63       0.63

FILE 'REGISTRY' ENTERED AT 14:11:46 ON 14 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 MAR 2003  HIGHEST RN 499099-49-9
DICTIONARY FILE UPDATES:  13 MAR 2003  HIGHEST RN 499099-49-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s xylometazoline
L1            2 XYLOMETAZOLINE

=> d 1-2

L1   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2003 ACS
RN   1218-35-5  REGISTRY
CN   1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-
```

dihydro-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)-, monohydrochloride (8CI)
OTHER NAMES:
CN Galazolin
CN Neo-Rinoleina
CN Neo-Synephrine II
CN Novorin
CN Olynth
CN Otrivin hydrochloride
CN Otrivine
CN Otrivine hydrochloride
CN Therapin
CN **Xylometazoline hydrochloride**
CN Xymelin
DR 8057-34-9, 28096-10-8
MF C16 H24 N2 . Cl H
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DIOGENES, EMBASE, IPA, MEDLINE, MRCK*, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (526-36-3)



● HCl

71 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
71 REFERENCES IN FILE CAPLUS (1962 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 526-36-3 REGISTRY
CN 1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Imidazoline, 2-(4-tert-butyl-2,6-dimethylbenzyl)- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 2-(4'-tert-Butyl-2',6'-dimethylbenzyl)imidazoline
CN 2-(4'-tert-Butyl-2',6'-dimethylphenylmethyl)imidazoline
CN 2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline
CN Ba 11391
CN Otriven
CN Otrivin
CN Otrivine
CN Otrix
CN Rhinoxilin
CN **Xylometazoline**
FS 3D CONCORD
MF C16 H24 N2

CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

203 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
203 REFERENCES IN FILE CAPLUS (1962 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s oxymetazoline
L2 2 OXYMETAZOLINE

=> d 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 2315-02-8 REGISTRY
CN Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, hydrochloride (7CI)
CN Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-, monohydrochloride (8CI)
OTHER NAMES:
CN 2,6-Dimethyl-4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride
CN 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride
CN 4-Way Nasal 12 Hour Spray
CN 4-Way Nasal Spray
CN 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol hydrochloride
CN Afrazine
CN Afrin
CN Afrin hydrochloride
CN Allerest 12 Hour Nasal Spray
CN Dristan Long-Lasting Nasal Mist
CN Duration
CN Duration 12 Hour Nasal Spray
CN H 990
CN Iliadin
CN Nafrine
CN Nasivin
CN Neo-Synephrine 12 Hour
CN Neo-Synephrine 12 Hour NTZ
CN Nostrilla

CN Ocuclear
CN Oxilin
CN **Oxymetazoline chloride**
CN **Oxymetazoline hydrochloride**
CN Sch 9384
MF C16 H24 N2 O . Cl H
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (1491-59-4)



● HCl

124 REFERENCES IN FILE CA (1962 TO DATE)
126 REFERENCES IN FILE CAPLUS (1962 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 1491-59-4 REGISTRY
CN Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl- (7CI, 8CI)
OTHER NAMES:
CN 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
CN 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
CN Hazol
CN Navasin
CN Navisin
CN Nezeril
CN Oxylazine
CN **Oxymetazoline**
CN Oxymethazoline
CN Rhinofrenol
CN Rhinolitan
CN Sinerol
FS 3D CONCORD
MF C16 H24 N2 O
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

602 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
602 REFERENCES IN FILE CAPLUS (1962 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> file caplus caold medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      16.76      17.39

FILE 'CAPLUS' ENTERED AT 14:14:01 ON 14 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAOLD' ENTERED AT 14:14:01 ON 14 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:14:01 ON 14 MAR 2003

=> d hist

     (FILE 'HOME' ENTERED AT 14:10:12 ON 14 MAR 2003)

     FILE 'REGISTRY' ENTERED AT 14:11:46 ON 14 MAR 2003
L1             2 S XYLOMETAZOLINE
L2             2 S OXYMETAZOLINE

     FILE 'CAPLUS, CAOLD, MEDLINE' ENTERED AT 14:14:01 ON 14 MAR 2003

=> s l1 or l2
L3          1411 L1 OR L2

=> s l3 and sorbitol or glycerol
L4        151332 L3 AND SORBITOL OR GLYCEROL

=> s l3 and (sorbitol or glycerol)
L5            22 L3 AND (SORBITOL OR GLYCEROL)

=> duplicate remove l5
DUPLICATE IS NOT AVAILABLE IN 'CAOLD'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L5
L6             22 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> d ibib abs 1-22

L6   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2003:147945  CAPLUS
TITLE:                    Pharmaceutical powder compositions containing
                          water-soluble active ingredients and alkylsiloxylated
```

silicate compounds
INVENTOR(S): Horie, Masahiko; Hattori, Masahiro; Kakihara, Kenichiro; Tanaka, Hiroaki
PATENT ASSIGNEE(S): Taiyo Sangyo K. K., Japan; New Hair Keshoka Honpo Co., Ltd.; Miyako Kagaku Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003055264	A2	20030226	JP 2001-277261	20010809

PRIORITY APPLN. INFO.: JP 2001-277261 20010809

AB The invention relates to a pharmaceutical powder compn. which easily shows a liq. form with small pressure, suitable for storage in a powder form and administration in a liq. form, wherein the compn. contains water-sol. active ingredient powder with/without of cyclodextrin or adsorbent, a liq. component, and an alkylsiloxylated silicate compd. Trimethylsiloxy silicate 7 g was mixed with a soln. contg. indomethacin 1, ethanol 3, glycerin 3 and water 100 % 93 g in a high-speed mixer to obtain a powder compn. The powder became liq. when touched with fingers.

L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:71907 CAPLUS
DOCUMENT NUMBER: 136:123679
TITLE: Enhancement of the action of central and peripheral nervous system agents with nitrous oxide
INVENTOR(S): Meyer, Petrus Johannes
PATENT ASSIGNEE(S): Pitmy International N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005851	A2	20020124	WO 2001-ZA99	20010719
WO 2002005851	A3	20020808		
WO 2002005851	C1	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: ZA 2000-3643 A 20000719

AB The invention provided a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the CPNS agents selected from the group of compds. acting on the central or peripheral nervous system, and for a formulation of such agents characterized in that the agent is formulated with an administration medium which is characterized in that it comprises a soln. of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable deriv. thereof selected from the group consisting of oleic acid, linoleic acid, .alpha.-linolenic acid, .gamma.-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5.omega.3], decosahexaenoic acid [C22:

6.omega.3], ricinoleic acid and derivs. thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the **glycerol** -PEG esters and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils such as castor oil with ethylene oxide. Solns. of nitrous oxide were prepd.

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:502726 CAPLUS
DOCUMENT NUMBER: 137:68164
TITLE: Pharmaceutical aerosols containing hydrofluorocarbon propellants and devices for their administration
INVENTOR(S): Goodman, Michael; Lindahl, Ake
PATENT ASSIGNEE(S): Biogland Ireland (R&D) Limited, Ire.
SOURCE: U.S., 8 pp., Cont.-in-part of U.S. Ser. No. 913,226, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6413496	B1	20020702	US 1999-325927	19990604
WO 9824420	A1	19980611	WO 1997-GB3360	19971204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710923	A	19980902	ZA 1997-10923	19971204

PRIORITY APPLN. INFO.:
GB 1996-25171 A 19961204
GB 1996-26449 A 19961220
US 1997-913226 B2 19970909
WO 1997-GB3360 A2 19971204

AB A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical compn. including a pharmaceutically active agent in a soln. of liquefied 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3 heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alc., polyol, (poly)alkoxy deriv., fatty acid alkyl ester, polyalkylene glycol, or DMSO. The device includes a valve arranged for delivering aerosol doses of said pharmaceutical compn. to the exterior of the container, and at least a portion of the device is formed from a polyester. For example, a compn. comprising beclomethasone dipropionate (BDP) with HFC- 134a suitable for use in a device of this invention was formulated from the following ingredients (by wt.): BDP 0.164%, ethanol 96% 4.992%, and HFC-134a. Each expelled dose of the this formulation is approx. 25 .mu.L and provides 50 .mu.g of BDP.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:868177 CAPLUS
DOCUMENT NUMBER: 136:11129
TITLE: Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
INVENTOR(S): Pinney, John M.; Henningfield, Jack E.; Taylor, L. David; Cone, Edward J.
PATENT ASSIGNEE(S): NPD LLC, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001089476	A1	20011129	WO 2001-US16068	20010521

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-573982 A 20000519

AB A transmucosal delivery system comprises a carrier for oral administration. A buffer is dispersed within the cavity, and there is sufficient buffer to achieve a predetd. pH within the oral cavity of a user. An active ingredient is dispersed within the carrier. At least a portion of the active ingredient is unionized at the predetd. pH, thereby permitting transmucosal absorption of the active ingredient within the oral cavity. A gum was prepd. contg. base 600, nicotine H tartrate 6.5, K2CO3 45, **sorbitol** 318.5, spearmint flavor 24, and menthol 6 mg.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with

hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:152460 CAPLUS
DOCUMENT NUMBER: 134:183528
TITLE: Phospholipid gels containing polyols
INVENTOR(S): Ibscher, Bernd; Fridrich, Ruland
PATENT ASSIGNEE(S): Merckle G.m.b.H., Germany
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013887	A2	20010301	WO 2000-EP7993	20000816
WO 2001013887	A3	20010920		
W: AU, CA, CZ, HU, JP, NO, PL, RU, SK, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19940227	A1	20010308	DE 1999-19940227	19990825
EP 1206245	A2	20020522	EP 2000-960468	20000816
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003507408	T2	20030225	JP 2001-518026	20000816
NO 2002000768	A	20020215	NO 2002-768	20020215

PRIORITY APPLN. INFO.: DE 1999-19940227 A 19990825
WO 2000-EP7993 W 20000816

AB A phospholipid gel which is stabilized against liquefying by adding a tetrahydric, pentahydric or hexahydric alc. or sugar is disclosed. The gel can be used for producing cosmetic and pharmaceutical formulations. Thus, a gel contained acyclovir 5.0, lecithin 23.5, propylene glycol 20.0, EtOH 10.0, **sorbitol** 2.5, phosphate buffer 0.05M and water to 100%.

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:656048 CAPLUS
DOCUMENT NUMBER: 136:16468
TITLE: Search of a topological pattern to evaluate toxicity of heterogeneous compounds
AUTHOR(S): Garcia-Domenech, R.; De Julian-Ortiz, J. V.; Duart, M. J.; Garcia-Torrecillas, J. M.; Anton-Fos, G. M.; Rios-Santamarina, I.; De Gregorio-Alapont, C.; Galvez, J.
CORPORATE SOURCE: Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular. Dpto de Quimica Fisica, Facultad de Farmacia, Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular. Dpto de Quimica Fisica, Facultad de Farmacia, Universidad de Valencia, Valencia, 46100, Spain
SOURCE: SAR and QSAR in Environmental Research (2001), 12(1-2), 237-254
CODEN: SQERED; ISSN: 1062-936X

PUBLISHER: Gordon & Breach Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mol. connectivity has been applied to the search of math. models able to predict the carcinogenic and teratogenic activity of a wide group of structurally heterogeneous compds. Through the linear discriminant anal. and the diagrams of distribution of pharmacol. activity, the classification criteria that minimizes the percentage of error are established. The easiness and speed of the calcn. of the descriptors used in this work make the models developed useful in data bases contg. a huge no. of compds.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:911060 CAPLUS
DOCUMENT NUMBER: 134:61546
TITLE: Stable xylometazoline and oxymetazoline solution
INVENTOR(S): Maerz, Frieder Ulrich
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078297	A2	20001228	WO 2000-EP5583	20000617
WO 2000078297	A3	20010301		
W: AE, AU, BG, BR, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BR 2000011950	A	20020312	BR 2000-11950	20000617
EP 1194145	A2	20020410	EP 2000-947853	20000617
EP 1194145	B1	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003502361	T2	20030121	JP 2001-504362	20000617
AT 232099	E	20030215	AT 2000-947853	20000617

PRIORITY APPLN. INFO.: US 1999-337789 A 19990622
WO 2000-EP5583 W 20000617
AB The invention relates to a biol. and chem. stable xylometazoline and/or oxymetazoline soln., contg. **glycerol** and/or **sorbitol** as adjuvants. Thus, a soln. contained xylometazoline-HCl 5.0, **sorbitol** 400.0, monosodium dihydrogen phosphate dihydrate 40.0, disodium monohydrogen phosphate dihydrate 6.5, and water 9698.5 mg/10 mL. The soln. decreased the growth of the microorganisms (E. coli).

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:144705 CAPLUS
DOCUMENT NUMBER: 132:185446
TITLE: Oral liquid mucoadhesive compositions containing colloidal particles of silica, titanium dioxide, or clay
INVENTOR(S): Dobrozsi, Douglas Joseph
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010530	A1	20000302	WO 1999-US19203	19990824
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338707	AA	20000302	CA 1999-2338707	19990824
AU 9955810	A1	20000314	AU 1999-55810	19990824
AU 748370	B2	20020606		
BR 9913141	A	20010508	BR 1999-13141	19990824
EP 1107734	A1	20010620	EP 1999-942430	19990824
EP 1107734	B1	20021023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523355	T2	20020730	JP 2000-565852	19990824
AT 226429	E	20021115	AT 1999-942430	19990824
NO 2001000831	A	20010219	NO 2001-831	20010219

PRIORITY APPLN. INFO.: US 1998-97577P P 19980824
WO 1999-US19203 W 19990824

AB The present invention relates to a per oral, oral or intranasal pharmaceutical mucoretentive, aq. liq. compn. comprising from about 2% to about 50%, by wt. of the compn., of colloidal particles of silica, titanium dioxide, clay, and mixts. thereof and a safe and effective amt. of a pharmaceutical active selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixts. thereof; wherein the compn. has a sedimentation vol. ratio of greater than about 0.90 and wherein the triggered viscosity ratio of the compn. is at least about 1.2. The present invention further relates to a method of coating the alimentary canal and nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amt. of the above compn. A pharmaceutical dispersion with enhanced mucosal coating and retention contained amorphous silica 6, sucralfate powder 20, 70% **sorbitol** soln. 20, sodium citrate dihydrate 1.25, and water q.s. 100%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:144703 CAPLUS
DOCUMENT NUMBER: 132:185444
TITLE: Oral liquid mucoadhesive compositions containing colloidal particles of silica, titanium dioxide, or clay
INVENTOR(S): Dobrozsi, Douglas Joseph
PATENT ASSIGNEE(S): The Procter and Gamble Company, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010528	A1	20000302	WO 1999-US19201	19990824

W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002009478	A1	20020124	US 1999-361542	19990727
CA 2338480	AA	20000302	CA 1999-2338480	19990824
AU 9955808	A1	20000314	AU 1999-55808	19990824
AU 753251	B2	20021010		
EP 1107732	A1	20010620	EP 1999-942428	19990824
EP 1107732	B1	20021120		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9913148	A	20010925	BR 1999-13148	19990824
JP 2002523353	T2	20020730	JP 2000-565850	19990824
AT 227978	E	20021215	AT 1999-942428	19990824
NO 2001000830	A	20010219	NO 2001-830	20010219
US 2002076421	A1	20020620	US 2001-21327	20011207

PRIORITY APPLN. INFO.: US 1998-97646P P 19980824
US 1999-361542 A3 19990727
WO 1999-US19201 W 19990824

AB The present invention relates to a per oral, oral or intranasal pharmaceutical mucoretentive, aq. liq. compn. comprising from about 2% to about 50%, by wt. of the compn., of colloidal particles of silica, titanium dioxide, clay, and mixts. thereof and a safe and effective amt. of a pharmaceutical active selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, sensory agents, gastrointestinal agents, and mixts. thereof; wherein the compn. has a sedimentation vol. ratio of greater than about 0.90 and wherein the triggered viscosity ratio of the compn. is at least about 1.2. The present invention further relates to a method of coating the alimentary canal and nasal mucosa, in particular to a method of preventing or treating symptoms of upper respiratory tract infections or upper respiratory tract tissue irritation or damage, by administering a safe and effective amt. of the above compn. A pharmaceutical dispersion with enhanced mucosal coating and retention contained amorphous silica 6, sucralfate powder 20, 70% **sorbitol** soln. 20, sodium citrate dihydrate 1.25, and water q.s. 100%.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:495155 CAPLUS
DOCUMENT NUMBER: 131:134646
TITLE: Nasal solutions having excellent and prolonged moisturizing properties
INVENTOR(S): Seidel, Matthias; Buckley, Christopher
PATENT ASSIGNEE(S): Novartis Consumer Health S.A., Switz.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938492	A1	19990805	WO 1999-EP555	19990128

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,

MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2311530	AA	19990805	CA 1999-2311530	19990128
AU 9925198	A1	19990816	AU 1999-25198	19990128
AU 741364	B2	20011129		
EP 1051155	A1	20001115	EP 1999-904823	19990128
EP 1051155	B1	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501884	T2	20020122	JP 2000-529226	19990128
AT 219657	E	20020715	AT 1999-904823	19990128
NZ 505919	A	20021025	NZ 1999-505919	19990128
US 2001053775	A1	20011220	US 2001-880678	20010613
US 2002193417	A1	20021219	US 2002-196520	20020715

PRIORITY APPLN. INFO.:	EP 1998-810069	A	19980130
	WO 1999-EP555	W	19990128
	US 2000-601123	B1	20000727
	US 2001-880678	A1	20010613

AB Liq. pharmaceutical compns. adapted to nasal administration having excellent and prolonged moisturizing properties are disclosed. A nasal drop contained xylometazoline hydrochloride 0.10, sodium dihydrogen phosphate dihydrate 0.50, disodium phosphate dodecahydrate 0.17, disodium edetate 0.05, 70% benzalkonium chloride 0.01, **sorbitol** 2.00, hydroxypropyl Me cellulose 0.50, sodium chloride 0.,40, and water 97.17%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:571732 CAPLUS
DOCUMENT NUMBER: 131:175106
TITLE: Herbal based nasal spray for treating nasal congestion
INVENTOR(S): Wiersma, Jack G.
PATENT ASSIGNEE(S): Nouveau Technologies, Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5948414	A	19990907	US 1998-47265	19980324

PRIORITY APPLN. INFO.: US 1998-47265 19980324

AB This invention relates to an improved herbal-based decongestant and antihistamine nasal spray which includes known constituents in specific ratios and further includes a saponin. The invention further relates to a method for treating nasal congestion which results in enhanced decongestant action and surprising curative effects. The preferred compn. for diln. with demineralized water to a total vol. of 3 L, contained menthol 3.2, camphor 6.0, eucalyptus oil 3.3, Cremophor EL 31.5, triterpene saponin (DAB-9 grade) 1.5, naphazoline.cntdot.HCl 1.5, chlorpheniramine maleate 6.0, benzalkonium chloride 1.2, and azulene (25 %) 6.3 g.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:293427 CAPLUS
DOCUMENT NUMBER: 129:8597
TITLE: Embedding and encapsulation of controlled release

particles
INVENTOR(S): Van Lengerich, Bernhard H.
PATENT ASSIGNEE(S): Van Lengerich, Bernhard H., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818610	A1	19980507	WO 1997-US18984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749915	A1	19980522	AU 1997-49915	19971027
AU 744156	B2	20020214		
EP 935523	A1	19990818	EP 1997-912825	19971027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002511777	T2	20020416	JP 1998-520558	19971027
NO 9902036	A	19990428	NO 1999-2036	19990428

PRIORITY APPLN. INFO.: US 1996-29038P P 19961028
US 1997-52717P P 19970716
WO 1997-US18984 W 19971027

AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temp. of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixt. The mixt. is extruded though a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, **glycerol** monostearate, and vegetable oil.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:389131 CAPLUS
DOCUMENT NUMBER: 127:9114
TITLE: Ophthalmic cromolyn gel preparation
INVENTOR(S): Bellmann, Guenther; Claus-Herz, Gudrun
PATENT ASSIGNEE(S): Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh, Germany
SOURCE: Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 770383	A1	19970502	EP 1996-117112	19961024
EP 770383	B1	20010711		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 19539532	A1	19970430	DE 1995-19539532	19951024
DE 19539532	C2	19990225		
WO 9715284	A1	19970501	WO 1996-EP4632	19961024
W: BR, CA, CN, CZ, JP, KR, MX, PL, RU, SG, TR, US, VN				
AT 202922	E	20010715	AT 1996-117112	19961024

PRIORITY APPLN. INFO.: DE 1995-19539532 A 19951024

AB The invention relates to an ophthalmic gel prepn. comprising at least one cromoglycine deriv. and at least one synthetic or natural polysaccharide, excluding cellulose derivs., or gum as the gel-forming agent. Disodium cromoglycate (I) is preferred compd. I causes very little or no eye irritation when formulated in a gel and the gel also avoids stickiness problems. An ophthalmic prepn. contained I 20, xanthan 13, **sorbitol** 38, Na edetate 0.1, Centrimid 0.1, and water 927.13 g.

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:319930 CAPLUS

DOCUMENT NUMBER: 122:122411

TITLE: Membrane Partition Coefficients Chromatographically Measured Using Immobilized Artificial Membrane Surfaces

AUTHOR(S): Ong, Shaowei; Liu, Hanlan; Qiu, Xiaoxing; Bhat, Ganapati; Pidgeon, Charles

CORPORATE SOURCE: School of Pharmacy, Purdue University, West Lafayette, IN, 47907, USA

SOURCE: Analytical Chemistry (1995), 67(4), 755-62
CODEN: ANCHAM; ISSN: 0003-2700

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Immobilized artificial membranes (IAMs) are chromatog. surfaces prepd. by covalently immobilizing cell membrane phospholipids. IAM surfaces mimic fluid cell membranes. Solute capacity factors (k'IAM) measured on IAM columns correlate very well with solute equil. partition coeffs. (Km') measured in fluid liposome systems. For 23 structurally unrelated compds., log(k'IAM) correlates with log(Km') with a linear correlation coeff. r = 0.907. This indicates that solute partitioning between the IAM bonded phase and the aq. mobile phase is similar to the solute partitioning between liposomes and the aq. phase. Although both IAM chromatog. and liposome partitioning can be used as in vitro methods to predict solute partitioning into cell membranes, IAM chromatog. is exptl. convenient compared to liposome systems. To study the effect of lipid structure on drug binding to IAMs, IAMs were prepd. from three different phosphatidylcholine ligands: (i) a diacylated phosphatidylcholine ligand, (ii) a single chain ether phosphatidylcholine ligand, and (iii) a single chain phosphatidylcholine ligand that lacks a **glycerol** backbone. Solute retention data were identical for all of these IAMs, and consequently, predictions of solute binding to fluid membranes were also identical. This indicates that the structure of the phosphatidylcholine ligand that is immobilized is not crit. for the binding of solutes. Since the structure is not important, the binding of solutes to membranes is a bulk phase property, i.e., it is the interface created by the ligands that dets. the solute binding properties, not the ligands themselves. Solute partitioning using octanol/water systems does not correlate with k'IAM unless a homologous series of hydrophobic solutes is being evaluated. It was demonstrated that drug partitioning into IAMs correlates very well with drug intestinal permeability, drug intestinal absorption, and oral drug absorption in animals.

L6 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:240982 CAPLUS

DOCUMENT NUMBER: 118:240982
TITLE: Medicinal aerosols containing butane and/or dimethyl ether as propellants
INVENTOR(S): Oliver, Martin J.; Jinks, Philip A.
PATENT ASSIGNEE(S): Minnesota Mining and Mfg. Co., USA
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9304671	A1	19930318	WO 1992-US7379	19920828
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
AU 9225738	A1	19930405	AU 1992-25738	19920828
EP 602181	A1	19940622	EP 1992-920106	19920828
R: DE, FR, GB, IT, SE				

PRIORITY APPLN. INFO.: GB 1991-18830 19910903
WO 1992-US7379 19920828

AB Aerosols which are substantially free of chlorofluorocarbons, comprise a drug, a **glycerol** phosphatide, and a propellant selected from butane, di-Me ether, and mixts. thereof. Soly. of the drugs in the propellant is enhanced in the presence of **glycerol** phosphatide. Thus, a stable aerosol soln. contained albuterol 2.00, Lipoid S100 (phsophatidylcholine) 14.00, and butane 563.00 mg/mL.

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:30174 CAPLUS
DOCUMENT NUMBER: 114:30174
TITLE: Fruity-flavored nasal decongestant pharmaceutical composition
INVENTOR(S): Kielley, James R.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4970240	A	19901113	US 1989-423075	19891018
AU 8945961	A1	19910426	AU 1989-45961	19891206
AU 637773	B2	19930610		
US 5114979	A	19920519	US 1990-576021	19900831

PRIORITY APPLN. INFO.: US 1989-423075 19891018

AB An aq., flavored, topical, nasal decongestant compn. is provided which contains an amt. of oxymetazoline or a pharmaceutically acceptable salt thereof sufficient to effect nasal decongestion and an amt. of a fruity flavor sufficient to mask the medicinal after-taste of the compn., together with an aq. carrier. Thus, an adult-strength formulation contained oxymetazoline-HCl 0.05, phenylmercuric acetate 0.002, benzalkonium chloride 0.02, glycine 0.3754, 70% (wt./vol.) **sorbitol** soln. 5.7143, cherry flavor 0.35 wt.%, q.s. with NaOH to pH 5.5-6.5, and q.s. with water to 1 mL.

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:125881 CAPLUS
DOCUMENT NUMBER: 106:125881
TITLE: Drug-containing chlorofluorocarbon aerosol propellent formulations

INVENTOR(S): Jinks, Philip Anthony; Bell, Alexander; Fischer, Franz Xaver
PATENT ASSIGNEE(S): Riker Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8604233	A1	19860731	WO 1986-GB1	19860102
W: AU, DK, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
IL 77467	A1	19901223	IL 1985-77467	19851227
AU 8653064	A1	19860813	AU 1986-53064	19860102
AU 577663	B2	19880929		
EP 209547	A1	19870128	EP 1986-900606	19860102
EP 209547	B1	19900912		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 62501906	T2	19870730	JP 1986-500323	19860102
JP 08011725	B4	19960207		
HU 42938	A2	19870928	HU 1986-935	19860102
HU 196303	B	19881128		
AT 56358	E	19900915	AT 1986-900606	19860102
ZA 8600045	A	19861029	ZA 1986-45	19860103
DD 241422	A5	19861210	DD 1986-286139	19860113
ES 550891	A1	19871016	ES 1986-550891	19860115
CA 1264297	A1	19900109	CA 1986-499583	19860115
FI 8603730	A	19860915	FI 1986-3730	19860915
FI 90014	B	19930915		
FI 90014	C	19931227		
DK 8604403	A	19860915	DK 1986-4403	19860915
NO 8603683	A	19860915	NO 1986-3683	19860915
NO 172727	B	19930524		
NO 172727	C	19930901		
US 4814161	A	19890321	US 1986-915971	19861110

PRIORITY APPLN. INFO.: GB 1985-1015 19850116
EP 1986-900606 19860102
WO 1986-GB1 19860102

AB **Glycerol** phosphatides, preferably phosphatidylcholines, are mixed with aerosol propellants, preferably Propellant 11, at 0.01:100 - 20:100 ratios of phosphatide to propellant, for more effective solubilization of drugs in aerosol formulations. Thus, a formulation contained Propellant 11 270, Propellant 12 1080, epikuron 200 14, and beclomethasone dipropionate 1 mg/mL.

L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:39611 CAPLUS
DOCUMENT NUMBER: 100:39611
TITLE: Tricyclic antidepressants for treating and preventing irritation of the mucous membranes of the nose
INVENTOR(S): Bernstein, Joel E.; Endicott, Clarence J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 93373	A1	19831109	EP 1983-104048	19830425

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

US 4603131	A	19860729	US 1982-372231	19820426
AU 8313923	A1	19831103	AU 1983-13923	19830426
CA 1198059	A1	19851217	CA 1983-426701	19830426

PRIORITY APPLN. INFO.: US 1982-372231 19820426

AB Sneezing, stuffiness, or drainage from nasal membrane irritation by pollution, allergy, or phys. irritants can be prevented by topical application (1-4 times daily) of an aq. soln. contg. 0.005-1.25% of a tricyclic antidepressant. The addn. of 0.01-1.0% of a vasoconstrictor gives solns. that can be used to treat irritated membranes. A prophylatic soln. contains imipramine-HCl [113-52-0] 0.05, NaH2PO4 0.368, Na2HPO4 0.026, **sorbitol** 4, benzalkonium chloride 0.01, di-Na EDTA 0.1, and H2O 95.466%. The addn. of 0.25% phenylephrine-HCl [61-76-7] with a decrease of H2O to 95.20% gives a soln. with vasoconstricting activity.

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:45404 CAPLUS
DOCUMENT NUMBER: 100:45404
TITLE: Solubilization of rat liver .alpha.1-adrenergic receptors. Agonist specific alteration in receptor binding affinity
AUTHOR(S): Wikberg, Jarl E. S.; Lefkowitz, Robert J.; Caron, Marc G.
CORPORATE SOURCE: Med. Cent., Duke Univ., Durham, NC, 27710, USA
SOURCE: Biochemical Pharmacology (1983), 32(21), 3171-8
CODEN: BCPCA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An improved method for the solubilization of the .alpha.1-adrenergic receptors in rat liver, utilizing digitonin, **glycerol**, and sonication, is described. The yield of solubilized receptors was .apprx.20%. The sol. receptors showed characteristics similar to the membrane-bound .alpha.1-receptors. However, after solubilization, the affinity for the agonists (-)norepinephrine [51-41-2] and (-)epinephrine [51-43-4] increased 35-66-fold when compared with the affinity in the membranes. The affinity for antagonists remained unchanged. A no. of synthetic partial agonists showed a less marked (5-10-fold) increase in affinity after solubilization. These data are consistent with the notion that these receptors might be capable of existing in 2 distinct conformational states with the high-affinity state for agonists being favored by solubilization.

L6 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1981:614903 CAPLUS
DOCUMENT NUMBER: 95:214903
TITLE: Alterations of phospholipid metabolism in rat cerebral cortex mince induced by cationic amphiphilic drugs
AUTHOR(S): Pappu, Anuradha S.; Hauser, George
CORPORATE SOURCE: Ralph Lowell Lab., McLean Hosp., Belmont, MA, 02178, USA
SOURCE: Journal of Neurochemistry (1981), 37(4), 1006-14
CODEN: JONRA9; ISSN: 0022-3042
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Cationic amphiphilic drugs (CADs) of varied clin. use were screened to det. their capacity to alter the pattern of labeling with 32Pi of cerebral cortex mince phospholipids. The altered phospholipid labeling patterns were qual. similar, the prominent features being reduced incorporation into phosphatidylcholine and increased incorporation into phosphatidic acid. Relative potencies were: (.+-.)-propranolol-HCl [3506-09-0] > chlorpromazine-HCl [69-09-0] = 4,4'-bis(diethylaminoethoxy) .alpha.,.beta.-diethyldiphenylethane [64280-25-7] > desipramine [50-47-5] > dibucaine-HCl [61-12-1] > pimozide [2062-78-4] > oxymetazoline-HCl [**2315-02-8**] = fenfluramine [458-24-2] = haloperidol [52-86-8] = chloroquine [54-05-7] > amphetamine-HCl

[2706-50-5] = no drug added. Propranolol was used to study the action of CADs further. Its effect was time- and dose-dependent, but in contrast with pineal gland, no label appeared in phosphatidyl-CMP (CDP-diacylglycerol), nor did dialysis of the mince to reduce diffusible substrates or exogenous addn. of substrates cause appearance of liponucleotide. Thus, lack of diffusible precursors is not responsible for CAD effects in vitro. Pulse-chase expts. with 32Pi and [2-3H] **glycerol** suggested that inhibition of phosphatidate phosphohydrolase [9025-77-8] may be partly responsible for the obsd. alterations in phospholipid labeling in the presence of CADs. The relation of these results to the induction of lipidosis by these drugs is discussed.

L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1978:45297 CAPLUS
DOCUMENT NUMBER: 88:45297
TITLE: Hormonal control of gluconeogenesis in tubule fragments from renal cortex of fed rats. Effects of .alpha.-adrenergic stimuli, glucagon, theophylline and papaverine
AUTHOR(S): MacDonald, David W. R.; Saggerson, E. David
CORPORATE SOURCE: Dep. Biochem., Univ. Coll., London, UK
SOURCE: Biochemical Journal (1977), 168(1), 33-42
CODEN: BIJOAK; ISSN: 0006-2936
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Gluconeogenesis in tubule fragments from the renal cortex of fed rats was stimulated by L-adrenaline (I) [51-43-4] (1.mu.M optimum) and by selective .alpha.-adrenergic agonists, e.g., (.+-.)-oxymetazoline-HCl (II) [**2315-02-8**] (0.1.mu.M), whereas .beta.-agonists were ineffective at concns. up to 10.mu.M. Gluconeogenesis stimulation by I was blocked by .alpha.-antagonists (10.mu.M), but unaffected by .beta.-antagonists. I stimulation of gluconeogenesis was rapid and sustained for at least 1 h, and some stimulation was obsd. in the absence of Ca. II was very potent in stimulating gluconeogenesis from pyruvate, lactate, or glutamate, but not from succinate or **glycerol**, and was ineffective in the absence of Ca. Glucagon [9007-92-5] had no effect on gluconeogenesis in the presence of 1.27mM Ca, but was inhibitory in 0.25mM Ca. Parathyrin [9002-64-6] stimulated gluconeogenesis in 1.27mM Ca. Glucagon, papaverine [58-74-2] and I increased cyclic AMP [60-92-4] in short incubations, but I also decreased cyclic GMP [7665-99-8]. II had no effect on either cyclic nucleotide. Theophylline [58-55-9] and papaverine decreased gluconeogenesis from pyruvate. Thus renal gluconeogenesis may be increased by .alpha.-adrenergic stimuli; cyclic AMP and cyclic GMP appear not to be involved in this stimulation.

=> d hist

(FILE 'HOME' ENTERED AT 14:10:12 ON 14 MAR 2003)

FILE 'REGISTRY' ENTERED AT 14:11:46 ON 14 MAR 2003
L1 2 S XYLOMETAZOLINE
L2 2 S OXYMETAZOLINE

FILE 'CAPLUS, CAOLD, MEDLINE' ENTERED AT 14:14:01 ON 14 MAR 2003
L3 1411 S L1 OR L2
L4 151332 S L3 AND SORBITOL OR GLYCEROL
L5 22 S L3 AND (SORBITOL OR GLYCEROL)
L6 22 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> s l6 and nasal
L7 6 L6 AND NASAL

=> d ibib 1-6

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:144705 CAPLUS
DOCUMENT NUMBER: 132:185446
TITLE: Oral liquid mucoadhesive compositions containing colloidal particles of silica, titanium dioxide, or clay
INVENTOR(S): Dobrozsi, Douglas Joseph
PATENT ASSIGNEE(S): The Procter & Gamble Company, USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010530	A1	20000302	WO 1999-US19203	19990824
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338707	AA	20000302	CA 1999-2338707	19990824
AU 9955810	A1	20000314	AU 1999-55810	19990824
AU 748370	B2	20020606		
BR 9913141	A	20010508	BR 1999-13141	19990824
EP 1107734	A1	20010620	EP 1999-942430	19990824
EP 1107734	B1	20021023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523355	T2	20020730	JP 2000-565852	19990824
AT 226429	E	20021115	AT 1999-942430	19990824
NO 2001000831	A	20010219	NO 2001-831	20010219

PRIORITY APPLN. INFO.: US 1998-97577P P 19980824
WO 1999-US19203 W 19990824
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:144703 CAPLUS
DOCUMENT NUMBER: 132:185444
TITLE: Oral liquid mucoadhesive compositions containing colloidal particles of silica, titanium dioxide, or clay
INVENTOR(S): Dobrozsi, Douglas Joseph
PATENT ASSIGNEE(S): The Procter and Gamble Company, USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010528	A1	20000302	WO 1999-US19201	19990824
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002009478	A1	20020124	US 1999-361542	19990727
CA 2338480	AA	20000302	CA 1999-2338480	19990824
AU 9955808	A1	20000314	AU 1999-55808	19990824
AU 753251	B2	20021010		
EP 1107732	A1	20010620	EP 1999-942428	19990824
EP 1107732	B1	20021120		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 9913148	A	20010925	BR 1999-13148	19990824
JP 2002523353	T2	20020730	JP 2000-565850	19990824
AT 227978	E	20021215	AT 1999-942428	19990824
NO 2001000830	A	20010219	NO 2001-830	20010219
US 2002076421	A1	20020620	US 2001-21327	20011207

PRIORITY APPLN. INFO.: US 1998-97646P P 19980824
US 1999-361542 A3 19990727
WO 1999-US19201 W 19990824
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:571732 CAPLUS
DOCUMENT NUMBER: 131:175106
TITLE: Herbal based **nasal** spray for treating **nasal** congestion
INVENTOR(S): Wiersma, Jack G.
PATENT ASSIGNEE(S): Nouveau Technologies, Inc., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5948414	A	19990907	US 1998-47265	19980324

PRIORITY APPLN. INFO.: US 1998-47265 19980324
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:495155 CAPLUS
DOCUMENT NUMBER: 131:134646
TITLE: **Nasal** solutions having excellent and prolonged moisturizing properties
INVENTOR(S): Seidel, Matthias; Buckley, Christopher
PATENT ASSIGNEE(S): Novartis Consumer Health S.A., Switz.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938492	A1	19990805	WO 1999-EP555	19990128

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,

KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2311530	AA	19990805	CA 1999-2311530	19990128
AU 9925198	A1	19990816	AU 1999-25198	19990128
AU 741364	B2	20011129		
EP 1051155	A1	20001115	EP 1999-904823	19990128
EP 1051155	B1	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002501884	T2	20020122	JP 2000-529226	19990128
AT 219657	E	20020715	AT 1999-904823	19990128
NZ 505919	A	20021025	NZ 1999-505919	19990128
US 2001053775	A1	20011220	US 2001-880678	20010613
US 2002193417	A1	20021219	US 2002-196520	20020715

PRIORITY APPLN. INFO.:
EP 1998-810069 A 19980130
WO 1999-EP555 W 19990128
US 2000-601123 B1 20000727
US 2001-880678 A1 20010613

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:30174 CAPLUS
DOCUMENT NUMBER: 114:30174
TITLE: Fruity-flavored **nasal** decongestant pharmaceutical composition
INVENTOR(S): Kielley, James R.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4970240	A	19901113	US 1989-423075	19891018
AU 8945961	A1	19910426	AU 1989-45961	19891206
AU 637773	B2	19930610		
US 5114979	A	19920519	US 1990-576021	19900831

PRIORITY APPLN. INFO.:
US 1989-423075 19891018

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:39611 CAPLUS
DOCUMENT NUMBER: 100:39611
TITLE: Tricyclic antidepressants for treating and preventing irritation of the mucous membranes of the nose
INVENTOR(S): Bernstein, Joel E.; Endicott, Clarence J.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 93373	A1	19831109	EP 1983-104048	19830425

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

US 4603131	A	19860729	US 1982-372231	19820426
AU 8313923	A1	19831103	AU 1983-13923	19830426
CA 1198059	A1	19851217	CA 1983-426701	19830426

PRIORITY APPLN. INFO.: US 1982-372231 19820426

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	82.11	99.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.32	-14.32

STN INTERNATIONAL LOGOFF AT 14:22:43 ON 14 MAR 2003